Decline in trial recruitment denying patients, ABPI warns
The decline in commercial clinical trial recruitment is denying patients participation in cutting-edge research, the Association of the British Pharmaceutical Industry (ABPI) has warned.
According to the ABPI’s annual clinical trials report, the number of patients recruited into UK industry clinical trials fell by 25% between 2022/23 and 2024/25. Participation from patients in commercial trials is now at its lowest level since 2017/18, the report finds.
While overall participation in clinical trials in England has increased since the pandemic, only 3.4% of participants in 2024 were recruited into industry trials in the NHS. Companies point to slow trial set-up times and significantly lower recruitment targets set by UK trial sites, compared to other European countries, as key reasons for the decline.
The Prime Minister Keir Starmer has committed to reducing clinical trial set-up times from around 250 to 150 days. This includes three elements: regulatory decisions within 60 days, sites opening to recruitment within 60 days of approval, and first patient recruited within 30 days of the trial opening.
The ABPI report shows that, while regulatory decisions were within their target timeframes, just 27% of UK trial sites opened to recruitment within the 60-day target, and only 41% recruited their first participant within 30 days.
“Industry clinical trials bring widespread benefits for patients, the NHS and the economy,” said Dr Janet Valentine, the ABPI’s Executive Director of Research and Innovation Policy.
“While the increase in the number of industry trials initiated in the UK is positive, the low number of patients taking part is selling UK patients short of the opportunity to participate in studies of the latest therapeutic innovations, which is especially vital where there are no other treatment options available.”
ABPI calls on UK to maintain global competitiveness
Despite slow set-up times for clinical trials, the ABPI report indicates some encouraging signs of progress. The number of new industry trials initiated in the UK in 2024 rose by 36% (578 trials, up from 426 in 2023), and the UK climbed to sixth place globally for Phase III trial starts in 2024, up from eighth place in 2023.
However, the report shows increasing competition from other nations, with China continuing to expand its global dominance in clinical trials, and Spain now the leading country for placing clinical trials in Europe.
Commercial clinical trials generated £7.4 billion ($9.8 billion) for the UK economy in 2022, including £1.2 billion ($1.6 billion) for the NHS. The ABPI is urging government and NHS leaders to accelerate reforms to trial delivery and increase patient recruitment, to maintain the UK’s global competitiveness.
In the report, the ABPI calls for research delivery sites to set and meet higher recruitment targets. Other recommendations include accelerating set-up times, ensuring executive-level accountability for clinical trials across the NHS and maximising the opportunity offered by the VPAG Clinical Trials Investment Programme.
“The government and system partners are working hard to improve the environment for delivering industry trials in the UK,” Dr Valentine added.
“Our report spotlights where these efforts could have the maximum effect, including taking advantage of the unique £300 million ($397 million) VPAG Clinical Trials Investment Programme, funded by industry to improve UK commercial trials delivery.”
Bruno Quinney, Content Team, DDW
